These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

698 related items for PubMed ID: 28274575

  • 21. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation.
    Ling LH, Kalman JM, Ellims AH, Iles LM, Medi C, Sherratt C, Kaye DM, Hare JL, Kistler PM, Taylor AJ.
    Circ Arrhythm Electrophysiol; 2013 Aug; 6(4):697-704. PubMed ID: 23884195
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy.
    Leyva F, Taylor RJ, Foley PW, Umar F, Mulligan LJ, Patel K, Stegemann B, Haddad T, Smith RE, Prasad SK.
    J Am Coll Cardiol; 2012 Oct 23; 60(17):1659-67. PubMed ID: 23021326
    [Abstract] [Full Text] [Related]

  • 26. Effect of Cardiac Resynchronization Therapy on Myocardial Fibrosis and Relevant Cytokines in a Canine Model With Experimental Heart Failure.
    Wang J, Gong X, Chen H, Qin S, Zhou N, Su Y, Ge J.
    J Cardiovasc Electrophysiol; 2017 Apr 23; 28(4):438-445. PubMed ID: 28127817
    [Abstract] [Full Text] [Related]

  • 27. Cardiac magnetic resonance-derived anatomy, scar, and dyssynchrony fused with fluoroscopy to guide LV lead placement in cardiac resynchronization therapy: a comparison with acute haemodynamic measures and echocardiographic reverse remodelling.
    Shetty AK, Duckett SG, Ginks MR, Ma Y, Sohal M, Bostock J, Kapetanakis S, Singh JP, Rhode K, Wright M, O'Neill MD, Gill JS, Carr-White G, Razavi R, Rinaldi CA.
    Eur Heart J Cardiovasc Imaging; 2013 Jul 23; 14(7):692-9. PubMed ID: 23175695
    [Abstract] [Full Text] [Related]

  • 28. Effects of cardiac resynchronization therapy on left ventricular remodeling and dyssynchrony in patients with left ventricular noncompaction and heart failure.
    Qiu Q, Chen YX, Mai JT, Yuan WL, Wei YL, Liu YM, Yang L, Wang JF.
    Int J Cardiovasc Imaging; 2015 Feb 23; 31(2):329-37. PubMed ID: 25392055
    [Abstract] [Full Text] [Related]

  • 29. Left ventricular resynchronization is mandatory for response to cardiac resynchronization therapy: analysis in patients with echocardiographic evidence of left ventricular dyssynchrony at baseline.
    Bleeker GB, Mollema SA, Holman ER, Van de Veire N, Ypenburg C, Boersma E, van der Wall EE, Schalij MJ, Bax JJ.
    Circulation; 2007 Sep 25; 116(13):1440-8. PubMed ID: 17785624
    [Abstract] [Full Text] [Related]

  • 30. Assessment of Diffuse Ventricular Myocardial Fibrosis Using Native T1 in Children With Repaired Tetralogy of Fallot.
    Yim D, Riesenkampff E, Caro-Dominguez P, Yoo SJ, Seed M, Grosse-Wortmann L.
    Circ Cardiovasc Imaging; 2017 Mar 25; 10(3):. PubMed ID: 28292861
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Systolic and diastolic myocardial mechanics in hypertrophic cardiomyopathy and their link to the extent of hypertrophy, replacement fibrosis and interstitial fibrosis.
    Nucifora G, Muser D, Gianfagna P, Morocutti G, Proclemer A.
    Int J Cardiovasc Imaging; 2015 Dec 25; 31(8):1603-10. PubMed ID: 26210792
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Cardiovascular magnetic resonance imaging to assess myocardial fibrosis in valvular heart disease.
    Podlesnikar T, Delgado V, Bax JJ.
    Int J Cardiovasc Imaging; 2018 Jan 25; 34(1):97-112. PubMed ID: 28642994
    [Abstract] [Full Text] [Related]

  • 35. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial.
    St John Sutton M, Linde C, Gold MR, Abraham WT, Ghio S, Cerkvenik J, Daubert JC, REVERSE Study Group.
    JACC Heart Fail; 2017 Mar 25; 5(3):169-178. PubMed ID: 28254122
    [Abstract] [Full Text] [Related]

  • 36. Left ventricular regional glucose metabolism in combination with septal scar extent identifies CRT responders.
    Degtiarova G, Claus P, Duchenne J, Bogaert J, Nuyts J, Vöros G, Willems R, Larsen CK, Aalen JM, Fjeld JG, Stokke C, Hopp E, Smiseth OA, Voigt JU, Gheysens O.
    Eur J Nucl Med Mol Imaging; 2021 Jul 25; 48(8):2437-2446. PubMed ID: 33416956
    [Abstract] [Full Text] [Related]

  • 37. Effect of lateral wall scar on reverse remodeling with cardiac resynchronization therapy.
    Birnie D, DeKemp RA, Ruddy TD, Tang AS, Guo A, Williams K, Wassenar R, Lalonde M, Beanlands RS.
    Heart Rhythm; 2009 Dec 25; 6(12):1721-6. PubMed ID: 19959118
    [Abstract] [Full Text] [Related]

  • 38. Myocardial T1 Measurement Predicts Beneficial LV Remodeling After Long-Term Heart Failure Therapy.
    Bradham WS, Bell SP, Adkisson DW, Smith HM, Harrell FE, Lawson MA, Ooi H, Sawyer DB, Kronenberg MW.
    J Card Fail; 2017 Mar 25; 23(3):262-265. PubMed ID: 27940336
    [Abstract] [Full Text] [Related]

  • 39. Usefulness of tissue Doppler velocity and strain dyssynchrony for predicting left ventricular reverse remodeling response after cardiac resynchronization therapy.
    Yu CM, Gorcsan J, Bleeker GB, Zhang Q, Schalij MJ, Suffoletto MS, Fung JW, Schwartzman D, Chan YS, Tanabe M, Bax JJ.
    Am J Cardiol; 2007 Oct 15; 100(8):1263-70. PubMed ID: 17920368
    [Abstract] [Full Text] [Related]

  • 40. Cardiac remodelling identified by cardiovascular magnetic resonance in patients with hepatitis C infection and liver disease.
    Ngu PJ, Butler M, Pham A, Roberts SK, Taylor AJ.
    Int J Cardiovasc Imaging; 2016 Apr 15; 32(4):629-36. PubMed ID: 26667447
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.